# Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI

Study · id `cardio:ct-nct03381755` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03381755](<https://clinicaltrials.gov/study/NCT03381755>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03381755

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03381755. Randomized; single masking; primary purpose prevention. Start 2018-01-01 (actual); primary completion 2019-12-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03381755, source copy `cardio:ctgov-nct03381755-2018-09-12`, retrieved 2026-10-31)
- Started: 2018-01-01 (actual) (ClinicalTrials.gov record NCT03381755, source copy `cardio:ctgov-nct03381755-2018-09-12`, retrieved 2026-10-31)
- Primary completion: 2019-12-14 (anticipated) (ClinicalTrials.gov record NCT03381755, source copy `cardio:ctgov-nct03381755-2018-09-12`, retrieved 2026-10-31)
- Completion: 2020-12-14 (anticipated) (ClinicalTrials.gov record NCT03381755, source copy `cardio:ctgov-nct03381755-2018-09-12`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03381755, source copy `cardio:ctgov-nct03381755-2018-09-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03381755-2018-09-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
- Condition: Acute Coronary Syndrome
- Intervention (Drug): half-dose ticagrelor
- Intervention (Drug): standard-dose ticagrelor
- Lead sponsor: First Affiliated Hospital of Harbin Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Harbin Medical University (`cardio:org-first-affiliated-hospital-of-harbin-medical-university`)

## Provenance

Content hash: c51de68bc29daf93fbcd19a070ec5073e8b5beb9f6b8b5fba849d123adf82353
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
